Efficacy of an Influenza Hemagglutinin‐Diphtheria Toxoid Conjugate Vaccine in Elderly Nursing Home Subjects During an Influenza Outbreak
- 1 March 1994
- journal article
- clinical trial
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 42 (3) , 245-251
- https://doi.org/10.1111/j.1532-5415.1994.tb01746.x
Abstract
To compare the efficacy of an influenza hemagglutinin-diphtheria toxoid conjugate vaccine with the commercially available influenza hemagglutinin-subunit vaccine in preventing influenza in older adults living in a nursing home. A prospective, randomized, double-blind vaccine trial with 5 months of follow-up after vaccination. Fourteen Wisconsin nursing homes. Nursing home residents at least 65 years old who were able to give informed consent and were free of malignancy and not receiving immunosuppressive therapy. Participants received, by intramuscular injection, 0.5 mL of a trivalent influenza vaccine containing 15 micrograms each of A/Leningrad/360/86 (H3N2), A/Taiwan/1/86 (H1N1), and B/Ann Arbor/1/86 (HA) or 0.5 mL of an influenza vaccine containing the same antigens conjugated to diphtheria toxoid (HA-D). Blood was obtained pre- and 1 month post-vaccination to assess for any vaccine-induced antibody titer change. Clinical surveillance for respiratory illness was performed twice weekly for 5 months. A record was kept of all signs and symptoms of new respiratory illness, and a viral culture and acute and convalescent sera were obtained. 204 participants received HA and 204 received HA-D. Both groups had similar baseline antibody levels to all influenza antigens. HA-D recipients seroconverted more frequently based on serum neutralizing activity (P < 0.05), had a greater increase in geometric mean titer (GMT), and sustained the increase in antibody titer longer than HA recipients. Vaccine hemagglutinin recall was greater in a subset of HA-D recipients as measured by lymphocyte proliferative assays (P < 0.05). During an outbreak of influenza A (H3N2 A/Shanghai/11/87-like and A/Victoria/7/87-like), fewer HA-D (29/195) than HA (43/204) recipients had laboratory-confirmed infection (P = 0.053), and, of these, fewer HA-D-treated subjects had lower respiratory tract involvement (5/29 HA-D and 17/43 HA) (P = 0.022). HA-D was more immunogenic in institutionalized elderly recipients and produced greater protection from influenza infection. Superior protection may be due to HA-D's ability to stimulate and recruit antigen-presenting cells, thus enabling the recipient to achieve and maintain functional antibody titers.Keywords
This publication has 23 references indexed in Scilit:
- Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulationVaccine, 1990
- Efficacy of Influenza Vaccine in Nursing HomesJAMA, 1985
- Safety and immunogenicity of haemophilus influenzae type b-polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of ageThe Journal of Pediatrics, 1985
- Influenza and aging: Age-related changes and the effects of thymosin on the antibody response to influenza vaccineJournal of Clinical Immunology, 1984
- Reactogenicity, Immunogenicity, and Antibody Persistence in Adults Given Inactivated Influenza Virus Vaccines--1978Clinical Infectious Diseases, 1983
- A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infectionEpidemiology and Infection, 1983
- Cause of Death in Very Old PeoplePublished by American Medical Association (AMA) ,1982
- HLA-RESTRICTED VIRUS-SPECIFIC CYTOTOXIC T-LYMPHOCYTE RESPONSES TO LIVE AND INACTIVATED INFLUENZA VACCINESThe Lancet, 1981
- Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans.Journal of Clinical Investigation, 1981
- INFLUENZA VACCINATION AND MORTALITY FROM BRONCHOPNEUMONIA IN THE ELDERLYThe Lancet, 1975